Stay updated with breaking news from Eric Siemers. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Ladies and gentlemen. Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2023 Conference Call and Webcast. At this time, all participants are in a listen-only mode.
People without memory problems could be diagnosed with Alzheimer's under a plan by an influential scientific panel dominated by members with ties to drug companies.
People without memory problems could be diagnosed with Alzheimer's under a plan by an influential scientific panel dominated by members with ties to drug companies.
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October...
- Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer -targeting antibody, to inform dose selection, plus further analyses of...